Literature DB >> 27060271

Incidence, predictive factors, and clinical impact of stent recoil in stent fracture lesion after drug-eluting stent implantation.

Masanobu Ohya1, Kazushige Kadota2, Shunsuke Kubo1, Takeshi Tada1, Seiji Habara1, Takenobu Shimada1, Hidewo Amano1, Yu Izawa1, Yusuke Hyodo1, Suguru Otsuru1, Daiji Hasegawa1, Hiroyuki Tanaka1, Yasushi Fuku1, Tsuyoshi Goto1, Kazuaki Mitsudo1.   

Abstract

BACKGROUND: Stent fracture (SF) after drug-eluting stent (DES) implantation was reported to be associated with target lesion revascularization (TLR). We have noted abnormal late acquired stent axial deformation in lesions after DES implantation, especially in SF lesions, and defined it as stent recoil (SR). We evaluated the incidence, predictive factors, and clinical impact of SR in SF lesions.
METHODS: Between 2003 and 2012, 5456 patients (11,712 lesions) underwent DES implantations and follow-up angiography within one year after the index procedure. SR was defined as an axial recoil deformation less than 80% of the stent diameter and SF was defined as the separation of stent segments or stent struts. SF and SR were confirmed by follow-up angiography. The primary endpoint was defined as clinically driven TLR.
RESULTS: SF was observed in 494 lesions (4.2%) and SR in 138 of SF lesions (27.9%). According to multinomial logistic regression analyses, severe calcification and ostial lesion in the right coronary artery were stronger predictive factors of SF with SR lesions. The cumulative incidences of any and clinically driven TLR at 5years were both significantly higher in the SF with SR group than in the SF without SR group (51.7% versus 35.0%, P<0.001; 22.2% versus 12.8%, P=0.019; respectively).
CONCLUSIONS: SR in SF lesions after DES implantation could be related to the lesion characteristics. SF with SR was highly associated with subsequent TLR compared with SF without SR.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Drug-eluting stent; Percutaneous coronary intervention; Stent deformation; Stent fracture

Mesh:

Year:  2016        PMID: 27060271     DOI: 10.1016/j.ijcard.2016.03.013

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  In-Stent Restenosis due to Stent Recoil After Third-Generation Drug-Eluting Stent Implantation.

Authors:  Yuta Kato; Atsushi Iwata; Masayuki Nakamura; Shin-Ichiro Miura; Keijiro Saku
Journal:  J Clin Med Res       Date:  2017-04-26

2.  The Impact of Aortic Valvular Calcium on Transcatheter Heart Valve Distortion.

Authors:  Akihiro Nakajima; Toru Naganuma; Haruhito Yuki; Hirokazu Onishi; Tatsuya Amano; Hiroto Yabushita; Hiroyoshi Kawamoto; Satoru Mitomo; Yosuke Kitanaka; Tatsuya Nakao; Naoyuki Kurita; Hisaaki Ishiguro; Satoko Tahara; Masaaki Okutsu; Shotaro Nakamura; Sunao Nakamura
Journal:  J Interv Cardiol       Date:  2021-01-05       Impact factor: 2.279

3.  A patient with an hourglass shaped fractured coronary stent.

Authors:  Andreas Y Andreou; Angelos Tyrlis
Journal:  Postepy Kardiol Interwencyjnej       Date:  2021-03-26       Impact factor: 1.426

4.  InSilc Computational Tool for In Silico Optimization of Drug-Eluting Bioresorbable Vascular Scaffolds.

Authors:  Miljan Milosevic; Milos Anic; Dalibor Nikolic; Bogdan Milicevic; Milos Kojic; Nenad Filipovic
Journal:  Comput Math Methods Med       Date:  2022-09-05       Impact factor: 2.809

5.  Incidence of coronary drug-eluting stent fracture: A systematic review and meta-analysis.

Authors:  Yang Chen; Dandan Li; Yanhui Liao; Xiongda Yao; Yuehua Ruan; Kai Zou; Hanhui Liao; Jingwen Ding; Hao Qin; Zuozhong Yu; Yuanbin Zhao; Longlong Hu; Renqiang Yang
Journal:  Front Cardiovasc Med       Date:  2022-08-23

6.  Application of in silico Platform for the Development and Optimization of Fully Bioresorbable Vascular Scaffold Designs.

Authors:  Miljan Milosevic; Milos Anic; Dalibor Nikolic; Vladimir Geroski; Bogdan Milicevic; Milos Kojic; Nenad Filipovic
Journal:  Front Med Technol       Date:  2021-10-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.